Drug Information

Drug General Information
Drug ID
D0D2TZ
Former ID
DIB011044
Drug Name
CMS-024-02
Synonyms
Tyroserleutide; Tyroservatide; CMS-024; CMS-024); Tyroserleutide (iv, cancer), China Medical System; Tyroserleutide (iv, cancer), Shenzhen Kangzhe Pharmaceuticals; Tyroservatide (cancer), Shenzhen Kangzhe Pharmaceuticals/ China Medical System Holdings; Tyroserleutide (iv, cancer), Shenzhen Kangzhe Pharmaceuticals/ China Medical System; Tyrosyl-seryl-leucine (cancer), Tianjin Medical University/Shenzhen Kangzhe Pharmaceutical
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 3 [523721]
Company
Shenzhen Kangzhe Pharmaceutical Co Ltd
Structure
Download
2D MOL

3D MOL
Canonical SMILES
N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(C)C)CO)Cc1ccc(<br />cc1)O
Target and Pathway
Target(s) Histone deacetylase Target Info Modulator [550907]
References
Ref 523721ClinicalTrials.gov (NCT01489566) Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients. U.S. National Institutes of Health.
Ref 550907US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.